Risk stratification and early detection biomarkers for precision HCC screening
Abstract
Hepatocellular carcinoma (HCC) mortality remains high primarily due to late diagnosis as a consequence of failed early detection. Professional societies recommend semi‐annual HCC screening in at‐risk patients with chronic liver disease to increase the likelihood of curative treatment receipt and improve survival. However, recent dynamic shift of HCC etiologies from viral to metabolic liver diseases has significantly increased the potential target population for the screening, whereas annual incidence rate has become substantially lower. Thus, with the contemporary HCC etiologies, the traditional screening approach might not be practical and cost‐effective. HCC screening consists of (i) definition of rational at‐risk population, and subsequent (ii) repeated application of early detection tests to the population at regular intervals. The suboptimal performance of the currently available HCC screening tests highlights an urgent need for new modalities and strategies to improve early HCC detection. In this review, we overview recent developments of clinical, molecular, and imaging‐based tools to address the current challenge, and discuss conceptual framework and approaches of their clinical translation and implementation. These encouraging progresses are expected to transform the current “one‐size‐fits‐all” HCC screening into individualized precision approaches to early HCC detection and ultimately improve the poor HCC prognosis in the foreseeable future.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 11, 2022
- Source ID
- 10.1002/hep.32779
Entities
People
- Ju Dong Yang
- Naoto Fujiwara
- Yi-Te Lee
- Yujin Hoshida
Organizations
- Cedars-Sinai Medical Center
- University of California, Los Angeles
- University of Texas Southwestern Medical Center